These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 30102201)

  • 21. Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial.
    Dueck AC; Scher HI; Bennett AV; Mazza GL; Thanarajasingam G; Schwab G; Weitzman AL; Rogak LJ; Basch E
    JAMA Oncol; 2020 Feb; 6(2):e193332. PubMed ID: 31556911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Using a modified Delphi procedure to select a PRO-CTCAE-based subset for patient-reported symptomatic toxicity monitoring in rectal cancer patients.
    Geurts YM; Peters F; Feldman E; Roodhart J; Richir M; Dekker JWT; Beets G; Cnossen JS; Bottenberg P; Intven M; Verheij M; de Ligt KM; Walraven I
    Qual Life Res; 2024 Nov; 33(11):3013-3026. PubMed ID: 39244711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validity and Reliability of the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events.
    Reeve BB; McFatrich M; Mack JW; Maurer SH; Jacobs SS; Freyer DR; Withycombe JS; Baker JN; Castellino SM; Lin L; Lucas NR; Hinds PS
    J Natl Cancer Inst; 2020 Nov; 112(11):1143-1152. PubMed ID: 31999349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Linking the European Organisation for Research and Treatment of Cancer Item Library to the Common Terminology Criteria for Adverse Events.
    Gilbert A; Piccinin C; Velikova G; Groenvold M; Kuliś D; Blazeby JM; Bottomley A
    J Clin Oncol; 2022 Nov; 40(32):3770-3780. PubMed ID: 35973158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Bruner DW; Hanisch LJ; Reeve BB; Trotti AM; Schrag D; Sit L; Mendoza TR; Minasian L; O'Mara A; Denicoff AM; Rowland JH; Montello M; Geoghegan C; Abernethy AP; Clauser SB; Castro K; Mitchell SA; Burke L; Trentacosti AM; Basch EM
    Transl Behav Med; 2011 Mar; 1(1):110-22. PubMed ID: 24073038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dutch translation and linguistic validation of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™).
    Veldhuijzen E; Walraven I; Mitchell SA; Moore EY; McKown SM; Lauritzen M; Kim KJ; Belderbos JSA; Aaronson NK
    J Patient Rep Outcomes; 2020 Oct; 4(1):81. PubMed ID: 33025309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrating the patient voice with clinician reports to identify a hepatocellular carcinoma-specific subset of treatment-related symptomatic adverse events.
    Speck RM; Lenderking WR; Shaw JW
    J Patient Rep Outcomes; 2017; 2():35. PubMed ID: 30175317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identifying symptomatic adverse events using the patient-reported outcomes version of the common terminology criteria for adverse events in patients with non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations.
    Zhu Y; Jean-Baptiste M; Lenderking WR; Bell JA; Revicki DA; Lin HM; Brake R; Reeve BB
    Cancer Med; 2023 Mar; 12(5):5494-5505. PubMed ID: 36583557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validation of the caregiver Pediatric Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events measure.
    Reeve BB; McFatrich M; Lin L; Lucas NR; Mack JW; Jacobs SS; Withycombe JS; Baker JN; Freyer DR; Hinds PS
    Cancer; 2021 May; 127(9):1483-1494. PubMed ID: 33332590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials.
    Veitch ZW; Shepshelovich D; Gallagher C; Wang L; Abdul Razak AR; Spreafico A; Bedard PL; Siu LL; Minasian L; Hansen AR
    J Natl Cancer Inst; 2021 Aug; 113(8):980-988. PubMed ID: 33616650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Electronic Patient-Reported Outcome Measures in Radiation Oncology: Initial Experience After Workflow Implementation.
    Hauth F; Bizu V; App R; Lautenbacher H; Tenev A; Bitzer M; Malek NP; Zips D; Gani C
    JMIR Mhealth Uhealth; 2019 Jul; 7(7):e12345. PubMed ID: 31342906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selecting a Subset Based on the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events for Patient-Reported Symptom Monitoring in Lung Cancer Treatment: Mixed Methods Study.
    Veldhuijzen E; Walraven I; Belderbos J
    JMIR Cancer; 2021 Sep; 7(3):e26574. PubMed ID: 34519658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of patient-reported outcomes item set to evaluate acute treatment toxicity to pelvic online magnetic resonance-guided radiotherapy.
    Møller PK; Pappot H; Bernchou U; Schytte T; Dieperink KB
    J Patient Rep Outcomes; 2021 Jun; 5(1):47. PubMed ID: 34160732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multi-method approach to selecting PRO-CTCAE symptoms for patient-reported outcome in women with endometrial or ovarian cancer undergoing chemotherapy.
    Christiansen MG; Pappot H; Jensen PT; Mirza MR; Jarden M; Piil K
    J Patient Rep Outcomes; 2023 Jul; 7(1):72. PubMed ID: 37462855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of the National Cancer Institute Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events to assess treatment tolerability in pulmonary arterial hypertension: qualitative patient research findings in current and former users of oral selexipag.
    Davis S; Edwards T; Norcross L; Fehnel S; Beaudet A; Eckart M; Fastenau J
    J Patient Rep Outcomes; 2023 Dec; 7(1):134. PubMed ID: 38108945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Routine Surveillance of Chemotherapy Toxicities in Cancer Patients Using the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Wang TQ; Samuel JN; Brown MC; Vennettilli A; Solomon H; Eng L; Liang M; Gill G; Merali Z; Tian C; Cheng NYH; Campbell M; Patel D; Liu AX; Liu G; Howell D
    Oncol Ther; 2018 Dec; 6(2):189-201. PubMed ID: 32700029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validity and reliability of the simplified Chinese patient-reported outcomes version of the common terminology criteria for adverse events.
    Yang SS; Chen L; Liu Y; Lu HJ; Huang BJ; Lin AH; Sun Y; Ma J; Xie FY; Mao YP
    BMC Cancer; 2021 Jul; 21(1):860. PubMed ID: 34315423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Linguistic and content validation of a German-language PRO-CTCAE-based patient-reported outcomes instrument to evaluate the late effect symptom experience after allogeneic hematopoietic stem cell transplantation.
    Kirsch M; Mitchell SA; Dobbels F; Stussi G; Basch E; Halter JP; De Geest S
    Eur J Oncol Nurs; 2015 Feb; 19(1):66-74. PubMed ID: 25190633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mapping child and adolescent self-reported symptom data to clinician-reported adverse event grading to improve pediatric oncology care and research.
    McFatrich M; Brondon J; Lucas NR; Hinds PS; Maurer SH; Mack JW; Freyer DR; Jacobs SS; Baker JN; Mowbray C; Wang M; Castellino SM; Barz Leahy A; Reeve BB
    Cancer; 2020 Jan; 126(1):140-147. PubMed ID: 31553494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Linguistic validation of the simplified Chinese version of the US National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™).
    Kkf C; Mitchell SA; Chan N; Ang E; Tam W; Kanesvaran R
    BMC Cancer; 2020 Nov; 20(1):1153. PubMed ID: 33243173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.